



10 November 2017

Byotrol plc

GRANT OF OPTIONS DIRECTOR SHAREHOLDINGS

The Board of Byotrol plc ('Byotrol' or the 'Company'), the specialist anti-microbial technology company, announces that on 9 November 2017, it granted a total of 10,296,750 options over the Company's ordinary shares of 0.25 pence each ("Options" and "Ordinary Shares" respectively) representing 2.56 per cent. of the issued share capital of the Company to two Directors and certain employees of the Company, upon the recommendation of the Company's Remuneration Committee.

Details of the awards to the two Directors and a PDMR of the Company are set out below (the "Director/PDMR Options"):

	Position	No. of New Options Granted	No. of Options held post Grant	Shareholding in Company	Percentage of fully diluted share capital
David Traynor	Chief Executive	1,000,000	6,900,000	4,850,514	2.92%
Dr Trevor Francis	Chief Technology Officer	2,375,000	6,325,000	2,253,216	2.13%
Denise Keenan	Head of Finance (PDMR)	1,792,500	3,217,500	-	0.80%
TOTAL		5,167,500			5.85%

The above Director/PDMR Options, which are exercisable at 4 pence per Ordinary Share over a seven year period, vest on the following basis;

- 30% vest after 12 months if the mid - share price averages over 5p for a 30 day period
- 35% vest after 24 months if the mid - share price averages over 7.5p for a 30 day period
- 35% vest after 36 months if the mid - share price averages over 10p for a 30 day period

The 5,167,500 Director/PDMR Options are being granted under the Company's Enterprise Management Incentive Scheme.

The remaining 5,129,250 Options are being awarded to a number of key employees of the Company ("Employee Options"). These Employee Options are also exercisable at 4 pence per Ordinary Share between 9 November 2018 and expire in tranches up to 9 May 2025. All 10,296,750 Options granted today will vest on any change of control of the Company.

Following the grant of the 10,296,750 Options, there will be 35,244,250 Options in issue representing 8.75% per cent. of the Company's issued share capital.

Enquiries:

Byotrol plc

John Langlands - Chairman
David Traynor – Chief Executive

01925 742 000

finnCap Ltd

Geoff Nash / Carl Holmes / James Thompson – Corporate Finance
Stephen Norcross / Richard Chambers – Corporate Broking

020 7220 0500

Notes to Editors:

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens.

Founded in 2005, the Company has developed the technology that creates easier, safer and cleaner lives.

For more information, please go to www.byotrol.co.uk

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	David Traynor
	Reason for the Notification	
a)	Position/status	Chief Executive
b)	Initial notification/Amendment	Initial
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Byotrol Plc
b)	LEI	213800AJMTSTIPA59A34
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the Financial instrument, type of instrument	options over ordinary shares of 0.25p each
	Identification code	GB00B0999995
b)	Nature of the transaction	Award of Options to subscribe for Ordinary Shares
c)	Price(s) and volume(s)	Volume – 1,000,000 Exercise Price – 4 pence
d)	Aggregated information:	See 4c) above
e)	Date of the transaction	9 November 2017
f)	Place of the transaction	Outside of a trading venue

	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Dr Trevor Francis

	Reason for the Notification	
a)	Position/status	Chief Technology Officer
b)	Initial notification/Amendment	Initial
7.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Byotrol Plc
b)	LEI	213800AJMTSTIPA59A34
8.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the Financial instrument, type of instrument	options over ordinary shares of 0.25p each
	Identification code	GB00B0999995
b)	Nature of the transaction	Award of Options to subscribe for Ordinary Shares
c)	Price(s) and volume(s)	Volume – 2,375,000 Exercise Price – 4 pence
d)	Aggregated information:	See 4c) above
e)	Date of the transaction	9 November 2017
f)	Place of the transaction	Outside of a trading venue

	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Denise Keenan
	Reason for the Notification	
a)	Position/status	Head of Finance and Company Secretary (PDMR)
b)	Initial notification/Amendment	Initial
11.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Byotrol Plc
b)	LEI	213800AJMTSTIPA59A34
12.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the Financial instrument, type of instrument	options over ordinary shares of 0.25p each
	Identification code	GB00B0999995
b)	Nature of the transaction	Award of Options to subscribe for Ordinary Shares
c)	Price(s) and volume(s)	Volume – 1,792,500

		Exercise Price – 4 pence
d)	Aggregated information:	See 4c) above
e)	Date of the transaction	9 November 2017
f)	Place of the transaction	Outside of a trading venue